Top Story Today
Novo Nordisk Wants You to Forget the 'Nordisk' Part
The Danish pharma giant behind Ozempic and Wegovy is rebranding to simply "Novo," ditching the "Nordisk" from every consumer-facing surface. The legal entity stays unchanged, but the message is clear: this company no longer wants to sound like a Nordic insulin maker. It wants to feel like Nike. The rebrand, built around a new platform called "Lasting Health Starts Now," follows Novo's push into direct-to-consumer pricing (a $199 introductory self-pay offer for Wegovy) and virtual care channels. Analysts are reserving judgment until Capital Markets Day on September 21, when the strategy behind the new business cards is supposed to arrive.
Why it matters: In a GLP-1 market that's becoming consumer-driven, the rebrand signals that even pharma's biggest names feel pressure to act like lifestyle brands. Whether the strategy matches the logo refresh will determine if this is a masterstroke or expensive wallpaper.
Read more →Deals and M&A
AstraZeneca's Reported $15 Billion Bet on a Keytruda Killer
AstraZeneca is reportedly negotiating a deal worth up to $15 billion with Summit Therapeutics for ivonescimab, a bispecific antibody that beat Keytruda in a head-to-head lung cancer trial. Patients on ivonescimab lived a median of 30.8 months versus 22.6 on Keytruda. If signed, it would rank among the largest licensing deals in biopharma history, though Summit is still pre-revenue and terms remain in flux.
Read more →Roche Pays $1.5 Billion for a Cancer Drug That Hasn't Touched a Human
Roche licensed a preclinical trispecific antibody from China's Simcere Zaiming for up to $1.53 billion ($75 million upfront). SIM-0660 targets CD19, CD79a, and CD3 simultaneously, designed to prevent the antigen escape that limits current bispecific therapies in blood cancers. It's a generational bet that trispecifics are the future of hematologic oncology.
Read more →GSK Commits $1.3 Billion to a Preclinical Cancer Missile
GSK licensed HUTCHMED's HMPL-A830, an antibody-drug conjugate carrying a KRAS inhibitor payload, for up to $1.295 billion ($110 million upfront). The dual-target approach blocks EGFR on the tumor surface while delivering a KRAS inhibitor inside, attacking two of the most stubborn oncology targets at once. HUTCHMED shares jumped roughly 14% on the news.
Read more →Europe's Next Obesity Drug Was Made in China
Italian pharma giant Menarini licensed Gan & Lee's bofanglutide for 39 European markets in a deal worth up to 726 million euros. The biweekly GLP-1 injection produced nearly 15% placebo-adjusted weight loss in Phase 2b, and dosing half as often as semaglutide could be a real differentiator. The deal is the latest example of Western companies raiding Chinese biotech pipelines for metabolic assets.
Read more →Clinical and Regulatory
AstraZeneca's Breast Cancer Pill Had One Job. It Missed.
Camizestrant failed to hit statistical significance in the pivotal SERENA-4 trial for first-line advanced breast cancer, showing only a numerical improvement in progression-free survival. The drug already has a narrow U.S. approval for ESR1-mutated patients, but the miss closes the door on a broad frontline franchise. Meanwhile, Eli Lilly's competing oral SERD imlunestrant just notched its second FDA approval.
Read more →A Daily Pill Shows 15 Months of Sustained Benefit in Huntington's Disease
Skyhawk Therapeutics reported that its oral drug SKY-0515 improved Huntington's patients by 1.59 points on a composite clinical score versus an external comparison group at 15 months, clearing the proposed threshold for clinical meaningfulness. The drug reduced mutant huntingtin protein by over 60%. In a field littered with high-profile failures (including Roche's tominersen), sustained clinical improvement from a pill is exceptionally rare.
Read more →Zealand Pharma's Gut Treatment Clears Europe's Final Scientific Hurdle
Europe's CHMP recommended approval of Zeydovio (glepaglutide) for short bowel syndrome, a rare condition where patients depend on IV nutrition to survive. In the pivotal trial, treated patients cut their weekly IV nutrition by 5.13 liters versus 2.85 for placebo, and five patients were weaned off parenteral support entirely. Full EU authorization is expected before year-end.
Read more →A Tiny Cancer Vaccine Trial Just Posted a Perfect Scorecard
Transgene's personalized cancer vaccine TG4050 kept all 16 treated patients disease-free at three years in HPV-negative head-and-neck cancer, while three of 16 control patients relapsed. The sample is small (elevator-sized, frankly), but in a disease where roughly half of patients die within five years, zero relapses across 41 months of follow-up sent the stock up 20%.
Read more →Policy and Regulation
The FDA Wants to Stop Losing Its Best Drug Trials to Australia
The FDA launched an Expedited IND Pilot Program designed to shave 6 to 12 months off the path to first-in-human trials in the U.S. Instead of submitting one giant regulatory package, sponsors can now get rolling feedback on individual components. The catch: trials must be conducted on American soil. Applications close October 30, with 8 to 10 spots in the first cohort.
Read more →